DG DISPATCH - AAP: New Formulations Of Antiepileptic Drugs Available For Children
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AAP: New Formulations Of Antiepileptic Drugs Available For Children

By Lara Pullen
Special to DG News

CHICAGO, IL -- November 2, 2000 -- Epilepsy affects up to 1 percent of the United States population and new formulations of older antiepileptic drugs provide an increased number of therapeutic tools in the treatment of this common neurological disease.

At the American Academy of Pediatrics (AAP) Annual Meeting, Dr. James W. Wheless of the University of Texas, Houston, presented an overview of new formulations of antiepileptics and their role in the treatment of children with epilepsy.

Tegretol-XR® and Carbatrol® are new formulations of carbamezapine that allow for twice daily dosing, while at the same time minimizing drug toxicity and improving efficacy. The application of extended release technology provides for steady levels of the drug and reduces the number of doses per day. Since noncompliance is the number-one cause of breakthrough seizures, the twice-daily dosing improves patient compliance and, therefore treatment, efficacy.

Topiramate sprinkle capsules (Topamax®) and lamotrigine chewable dispersible tablets (Lamictal®) can be useful for the treatment of younger patients who will not yet swallow tablets.

Diazepam (Diastat®) now comes in a rectal gel formulation that has proven useful for the treatment of acute seizure exacerbations. Intravenous valproate (Depacon®) and fosphenytoin (Cerebyx®) allow for the treatment of acute seizures without significant peripheral venous side effects.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities